These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 32196851)

  • 1. Resveratrol for protection against statin toxicity in C2C12 and H9c2 cells.
    Attalah Nee Rezkallah C; Thongkum A; Zhu C; Chen QM
    J Biochem Mol Toxicol; 2020 Jun; 34(6):e22484. PubMed ID: 32196851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class.
    Hoffman KB; Kraus C; Dimbil M; Golomb BA
    PLoS One; 2012; 7(8):e42866. PubMed ID: 22936996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lysophosphatidic Acid Inhibits Simvastatin-Induced Myocytoxicity by Activating LPA Receptor/PKC Pathway.
    Won KJ; Goh YJ; Hwang SH
    Molecules; 2020 Mar; 25(7):. PubMed ID: 32230890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Possible mechanisms underlying statin-induced skeletal muscle toxicity in L6 fibroblasts and in rats.
    Itagaki M; Takaguri A; Kano S; Kaneta S; Ichihara K; Satoh K
    J Pharmacol Sci; 2009 Jan; 109(1):94-101. PubMed ID: 19129682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.
    Neuvonen PJ; Backman JT; Niemi M
    Clin Pharmacokinet; 2008; 47(7):463-74. PubMed ID: 18563955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statin-related neurocognitive disorder: a real-world pharmacovigilance study based on the FDA adverse event reporting system.
    Xiao M; Li L; Zhu W; Wu F; Wu B
    Expert Rev Clin Pharmacol; 2024 Mar; 17(3):255-261. PubMed ID: 38275183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proinsulin C-Peptide Enhances Cell Survival and Protects against Simvastatin-Induced Myotoxicity in L6 Rat Myoblasts.
    Essid SM; Bevington A; Brunskill NJ
    Int J Mol Sci; 2019 Apr; 20(7):. PubMed ID: 30987105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of simvastatin myotoxicity: The role of autophagy flux inhibition.
    Emami A; Shojaei S; da Silva Rosa SC; Aghaei M; Samiei E; Vosoughi AR; Kalantari F; Kawalec P; Thliveris J; Sharma P; Zeki AA; Akbari M; Gordon JW; Ghavami S
    Eur J Pharmacol; 2019 Nov; 862():172616. PubMed ID: 31449810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperlipidaemia alone and in combination with acidosis can increase the incidence and severity of statin-induced myotoxicity.
    Taha DA; Zgair A; Lee JB; de Moor CH; Barrett DA; Bruce KD; Sungelo M; Eckel RH; Gershkovich P
    Eur J Pharm Sci; 2017 Mar; 100():163-175. PubMed ID: 28104473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world pharmacogenetics of statin intolerance: effects of SLCO1B1, ABCG2 , and CYP2C9 variants.
    Lönnberg KI; Tornio A; Hirvensalo P; Keskitalo J; Mustaniemi AL; Kiiski JI; Filppula AM; Niemi M
    Pharmacogenet Genomics; 2023 Sep; 33(7):153-160. PubMed ID: 37490620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects.
    Schaefer EJ; McNamara JR; Tayler T; Daly JA; Gleason JL; Seman LJ; Ferrari A; Rubenstein JJ
    Am J Cardiol; 2004 Jan; 93(1):31-9. PubMed ID: 14697462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
    Plans-Rubió P
    Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes.
    Masters BA; Palmoski MJ; Flint OP; Gregg RE; Wang-Iverson D; Durham SK
    Toxicol Appl Pharmacol; 1995 Mar; 131(1):163-74. PubMed ID: 7878672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipophilic but not hydrophilic statins selectively induce cell death in gynaecological cancers expressing high levels of HMGCoA reductase.
    Kato S; Smalley S; Sadarangani A; Chen-Lin K; Oliva B; Brañes J; Carvajal J; Gejman R; Owen GI; Cuello M
    J Cell Mol Med; 2010 May; 14(5):1180-93. PubMed ID: 19432822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statin-associated memory loss: analysis of 60 case reports and review of the literature.
    Wagstaff LR; Mitton MW; Arvik BM; Doraiswamy PM
    Pharmacotherapy; 2003 Jul; 23(7):871-80. PubMed ID: 12885101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the Effects of Statins on A549 Nonsmall-Cell Lung Cancer Cell Line Lipids Using Fourier Transform Infrared Spectroscopy: Rosuvastatin Stands Out.
    Aksoy HN; Ceylan C
    Lipids; 2021 May; 56(3):289-299. PubMed ID: 33611813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study).
    Jones P; Kafonek S; Laurora I; Hunninghake D
    Am J Cardiol; 1998 Mar; 81(5):582-7. PubMed ID: 9514454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia.
    Gentile S; Turco S; Guarino G; Sasso CF; Amodio M; Magliano P; Salvatore T; Corigliano G; Agrusta M; De Simone G; Gaeta I; Oliviero B; Torella R
    Diabetes Obes Metab; 2000 Dec; 2(6):355-62. PubMed ID: 11225965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.